Your browser doesn't support javascript.
loading
Less than whole uterus irradiation for patients with locally advanced cervical cancer.
Hui, Caressa; Ewongwo, Agnes; Mendoza, Maria G; Kozak, Margaret M; Jackson, Scott; Fu, Jie; Kidd, Elizabeth.
Afiliação
  • Hui C; Department of Radiation Oncology, Stanford University, United States.
  • Ewongwo A; Department of Radiation Oncology, Stanford University, United States.
  • Mendoza MG; Department of Radiation Oncology, Stanford University, United States.
  • Kozak MM; Department of Radiation Oncology, UT Southwestern Medical Center, United States.
  • Jackson S; Department of Radiation Oncology, Stanford University, United States. Electronic address: scott9@stanford.edu.
  • Fu J; Department of Radiation Oncology, Stanford University, United States.
  • Kidd E; Department of Radiation Oncology, Stanford University, United States. Electronic address: ekidd@stanford.edu.
Radiother Oncol ; 194: 110199, 2024 05.
Article em En | MEDLINE | ID: mdl-38438017
ABSTRACT

INTRODUCTION:

Current consensus guidelines for definitive cervical cancer intensity modulated radiation therapy (IMRT) recommend inclusion of the entire uterus within the clinical target volume, however this is debated. We aimed to evaluate outcomes of patients with cervical cancer who were treated with less than whole uterus irradiation.

METHODS:

We identified 109 patients with FIGO Stage IB-IVA cervical cancer treated definitively with concurrent chemoradiation, including IMRT and brachytherapy, from 2010 to 2022 at a single institution where the practice was to include the gross cervix tumor with an internal target volume with differences in bladder filing accounted for, plus additional 5 mm planning target volume (PTV) margin. Local, regional, and distant recurrences were analyzed using competing risk methods, and a Wilcoxon rank sum test was performed to assess differences in dose to organs at risk based on the proportion of the uterus included in the PTV, with the median proportion of the uterus included (75 %) used as the cut-point.

RESULTS:

The median follow-up time was 65 months (range 3-352 months). The 2-year cumulative incidence of LR for the entire cohort was 4.2 % (95 % confidence interval [CI] 1.3-9.7). Compared with patients who had ≥ 75 % of the uterus included in the PTV, patients who had < 75 % of the uterus included in the PTV had significantly lower bowel D200cc (p = 0.02). The cumulative incidence of local failure (LR) was not significantly different between the two groups.

CONCLUSIONS:

Including less than the whole uterus for definitive cervix cancer IMRT does not seem to compromise local control. Less than whole uterus irradiation could be considered for carefully selected cervix cancer patients to decrease bowel dose and possible treatment-related toxicity.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Útero / Braquiterapia / Neoplasias do Colo do Útero / Radioterapia de Intensidade Modulada / Quimiorradioterapia Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Radiother Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Útero / Braquiterapia / Neoplasias do Colo do Útero / Radioterapia de Intensidade Modulada / Quimiorradioterapia Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Radiother Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos